Navigation Links
RNL BIO Co. Ltd. stellt IND-Antrag, um klinische Phase-II-Studie des RNL-JointStem gegen Arthrose in den Vereinigten Staaten einzuleiten
Date:5/3/2013

ssiv zu Lähmungen führt, in erster Linie den Knorpel befällt und mit Veränderungen des Knochens verbunden ist. Knorpel verfügt über eine eingeschränkte intrinsische Heil- und Regenerationsfähigkeit.

Mit dieser Studie

Aufgrund der steigenden Inzidenz degenerativer Arthritis, der alternden Bevölkerung und der ineffizienten Therapieoptionen sind neue Strategien zum Knorpelaufbau erforderlich. Der Markt für ein therapeutisch wirksames Produkt für diese Indikation ist Schätzungen zufolge sehr groß.

Informationen zu IND-Anträgen

Der IND-Antrag (Investigational New Drug) ist Teil eines Zulassungsverfahrens zur Durchführung klinischer Untersuchungen in den Vereinigten Staaten. Ein IND-Antrag ist immer dann erforderlich, wenn die Durchführung einer klinischen Untersuchung in den Vereinigten Staaten beabsichtigt wird. Ein IND-Antrag enthält Informationen über die Qualität, Herstellung und Kontrolle eines Arzneimittelkandidaten sowie Daten aus präklinischen Studien und Angaben bezüglich des beabsichtigten Einsatzzwecks. Eine grundsätzliche Nutzen-Risiko-Bewertung sowie kritische Analysen präklinischer Daten unter Berücksichtigung aller potenziellen Risiken und Vorteile der vorgeschlagenen Studie müssen ebenfalls Teil des IND-Antrags sein.

Informationen zu klinischen Phase-II-Studien

Studien an klinischen Interventionen auf Basis von Biologika, wozu auch autologe, aus menschlichem Fett gewonnene Stammzellen gehören, unterliegen strengsten Kontrollen des Center for Biologics Evaluation and Research (CBER) der FDA. Nachdem das CBER und das örtliche Institutional Review Board (IRB) den Arzneimittelkandidaten für akzeptabel befunden haben, besteht die FDA auf die Durchführung einer Reihe mehrstufiger klinischer Studien. In Phase I ste
'/>"/>

SOURCE RNL BIO
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Taiho Pharmaceutical stellt Zulassungsantrag zur Herstellung und Vermarktung des neuartigen Antitumormittels TAS-102
2. Dr. Joachim Schorr (PhD) zum Chief Scientific Officer von Caris Life Sciences bestellt
3. Harvest Technologies Corporation erhält CE-Kennzeichnung für erweiterte klinische Indikation zur Behandlung nicht optionaler kritischer Extremitätenischämie
4. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
5. IDEV gibt Ergebnisse von Studie zur Revaskularisation mit Supera an echten Patienten (RESTORE) bekannt - Studie demonstriert positive klinische Ergebnisse bei schwerkranken Patienten mit langen Läsionen
6. Neue klinische Richtlinien für ältere Patienten mit Typ 2 Diabetes, um einen europaweiten Pflegenotstand zu verhindern
7. MR Solutions bringt vollständige Reihe heliumfreier präklinischer Magnetresonanztomographen auf den Markt
8. Neuartige Krebsimmuntherapie für den Beginn klinischer Studien bereit
9. Acutus Medical, Inc. erprobt erstmals seinen Echtzeit-3D-Bildgebungskatheter von CT/MRI-Qualität in einer klinischen Studie am Menschen
10. RNL BIO Co. Ltd. Files IND To Commence Phase II Clinical Trial Of RNL-JointStem For Osteoarthritis In The United States
11. RNL BIO Co. Ltd. lämnar in IND-ansökan om att påbörja klinisk fas II-prövning av RNL-JointStem för artros i USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... DALLAS , September 17, 2014 ... Electronics Market by Component (Sensor, Battery, Memory Device, Display, ... and Fitness & Wellness), and by Geography - Global ... of medical electronics market is expected to reach $56.50 ... from 2014 to 2020. Browse 235 market ...
(Date:9/17/2014)... , Sept. 17, 2014  NuView Life Sciences, ... licensing and collaboration agreement with Otsuka Pharmaceutical Co., ... investigative genomic-based diagnostic biomarker to detect cancers of ... all other future diagnostic-imaging applications. NuView retains all ... delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... 17, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... earned a $4 million milestone payment from Achaogen, ... the initiation of a Phase 3 study of ... gram-negative bacterial infections.  The Phase 3 study is ... efficacy and safety of plazomicin compared to colistin ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
... 2011 Promax Applications Group ( www.promaxtpo.com ), ... and optimization solutions, today announced that Kimberly-Clark Corporation ... Trade Promotion Management (TPM) and Optimization (TPO) solution ... the world,s most recognized consumer brands sold in ...
... Va., March 1, 2011 Health Diagnostic Laboratory ... its partnership to develop a novel laboratory developed ... venture developing diagnostic test and surgical therapy solutions ... disease (CVD), coronary heart disease (CHD) and stroke ...
Cached Medicine Technology:Kimberly-Clark Corporation Selects Promax as its North America Trade Promotion Management and Optimization Solution Provider 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Partners With Gamma Therapeutics to Offer Breakthrough Diagnostic Assay for Heart Attack and Stroke Risk 3
(Date:9/17/2014)... Dr. Shalev is a Texas native, and grew up in ... University of Texas, and graduated with a Bachelors of Business ... lay in dentistry, and she went on to receive a ... Science Center at Houston School of Dentistry. Dr. Shalev practices ... Greater Houston Dental Society, and the Texas Dental Association. ...
(Date:9/17/2014)... ADVOCATE, the premier provider of radiology ... they have been awarded the exclusive billing agreement ... Indiana. , ADVOCATE will deliver a ... suite of billing process software functionality called Experience ... and data quality consistency by ensuring a timely, ...
(Date:9/17/2014)... Pittsburgh, PA (PRWEB) September 17, 2014 ... their exercise - even when they're already practicing or ... I was inspired to design a special fitness system ... or playing baseball or football," said an inventor from ... the MOBILITY FITNESS SYSTEM, which maximizes a body workout ...
(Date:9/17/2014)... announced today that will analyze how changes in ... contribute to healthy aging. , Conducted by ... a $10 million unrestricted gift from the Amway ... identify lifestyle and environmental factors that may help ... age. WELL will be designed, conducted, and analyzed ...
(Date:9/17/2014)... chromosomes could hold the key to a better understanding of ... according to new research from the University of Leeds. ... factor for melanoma. , It is well known that pigmentation ... at risk of developing melanoma. For example, paler people should ... easily. , It now appears that another risk factor is ...
Breaking Medicine News(10 mins):Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 2Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 3Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Chromosome buffers hold key to better melanoma understanding 2
... IVIG worked. Its ability to treat autoimmune diseases seemed ... immunoglobulin (IVIG) is a complex mixture of IgG antibodies ... from thousands of people, and is only FDA-approved to ... it off-label with varied success in patients with lupus, ...
... geographic convenience and the quality of services that can ... to an article// in the latest edition of the ... a developing trend towards urban centralisation of surgical services, ... care standards. ,However, this creates geographical distances ...
... The Public Works and Government Services Canada said that there ... programs this year.// ,The vaccine instead of being ... in the month of November. Dr. Sheela Basrur, Ontario's chief ... by the beginning of the flu season. Public Works buys ...
... a study conducted by Prof Bernard a senior lecturer at ... found that more number// of rural people of heart attacks ... ,Statistics show that heart disease mortality rates in rural areas ... in women than in urban areas. But the solution to ...
... Australians who have type 2 diabetes could also be at ... the latest issue of the Medical Journal of Australia.// ... Renal Impairment cO-existing with NIDDM (non-insulin dependent diabetes mellitus) - ... ever undertaken in Australian general practice. ,NEFRON examined ...
... A study in Britain has found that nearly one-third of ... purpose, due to rupture, or simply slipping off// during sex, ... ,NOP world undertook a survey of nearly 497 people for ... nearly 64% were groping in the dark about the reasons ...
Cached Medicine News:Health News:Single Sugar Enables Antibody to Treat Inflammation 2Health News:Single Sugar Enables Antibody to Treat Inflammation 3Health News:Bolster Rural Surgical Services 2
... is a rapid latex agglutination ... of Helicobacter pylori total antibodies ... in the diagnosis of infection ... is intended for use to ...
... capillary electrophoresis system is designed to ... The CAPILLARYS 2 utilizes liquid flow ... diagnostic setting. Through continuous sample feed ... narrow capillary tubes functioning concurrently, a ...
Inquire...
These Iron Control Slides make an excellent addition to your laboratory. Packed ten (10) control slides per box. Use SDL's Snap n' Stain for Iron Staining Kit alongside to save time an money mixing r...
Medicine Products: